This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Harvard College, Massachusetts Eye and Ear Infirmary, The General Hospital Corporation. Active years: 2024-2026.
Company Filing History:
2 out of 3,071 
1 out of 276 
1 out of 3,071 
Years Active: 2024-2026
Title: Maryna V Ivanchenko: Innovator in Gene Therapy
Introduction
Maryna V Ivanchenko is a prominent inventor based in Cambridge, MA (US). She has made significant contributions to the field of gene therapy, particularly in the treatment of hearing and vision loss. With a total of 2 patents, her work focuses on innovative solutions for genetic disorders.
Latest Patents
Ivanchenko's latest patents include groundbreaking research on AAV vectors encoding mini-PCDH15. This patent addresses compositions, nucleic acids, vectors, and methods useful for treating hearing loss and/or blindness, specifically Usher Syndrome type IF. The disclosure provides isolated nucleic acids, vectors, and rAAV.9.PHP.B that comprise a transgene encoding a mini-PCDH15, along with methods for treating hearing loss. Additionally, her patent on recombinant adeno-associated virus encoding clarin-1 focuses on compositions and methods for treating hereditary hearing loss and/or vision loss, particularly Usher Syndrome, Type 3A. This includes a recombinant adeno-associated virus comprising an AAV-S capsid protein and an isolated nucleic acid with a transgene for expressing a clarin-1 protein.
Career Highlights
Maryna has worked at prestigious institutions such as Harvard College and The Ohio State University. Her research has been pivotal in advancing the understanding and treatment of genetic conditions affecting sensory functions.
Collaborations
Throughout her career, Ivanchenko has collaborated with notable colleagues, including David P Corey and Killian S Hanlon. These partnerships have enhanced her research and contributed to the development of innovative therapies.
Conclusion
Maryna V Ivanchenko is a trailblazer in the field of gene therapy, with a focus on addressing critical health issues related to hearing and vision loss. Her patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.